AngioDynamics (ANGO) Misses Q1 EPS by 2c, Revenues Beat; Offers FY19 Revenue Outlook Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
AngioDynamics Reports Fiscal 2019 First Quarter Financial Results
September 27, 2018 7:00 AM EDTFiscal 2019 First Quarter Highlights
Net sales of $85.3 million, flat versus prior year Gross margin expanded 380 basis points year over year to 52.1% GAAP EPS of $(0.01) per share; adjusted EPS of $0.16 per share Cash used in operations of $8.9 million; capital expenditures of $0.7 million Announced two acquisitions as part of the Companys strategic focus on building a continuum of care within the oncology space; BioSentry Tract Sealant System technology from Surgical Specialties, LLC... More